recommandations ssgo dépistage cancer du col utérin©sentations/grssgo mars... · dépistage...

39
Recommandations SSGO dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

Upload: dinhhanh

Post on 31-Aug-2018

216 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

Recommandations SSGOdeacutepistage cancer du col uteacuterin

Pr Patrick Petignat

University Hospitals of Geneva

GRSSGO 2018

Pap test for cervical cancer screening A success story

bull Introduce essentially by gynecologists in last 60

(annual control)

bull Opportunist

bull Cytology-based (conventional ndash LBC)

bull HPV for ASCUS triage

Cervical cancer screening Switzerland

Incidence CH 53 100 000NICER Cancer IncidenceSwitzerland wwwnicerorgenstatistics-atlascancerincidenceaccessed 01 08 2014

bull Participation rate Switzerland 70-80ndash Belgium 61ndash Norway 866ndash England 785-835

Richard et al Cancer Epidem 2015Arbyn et al PlosOne 2015Bang et al J Public Health 2012Jeangros et al Eur J Public Health 2016

Swiss CC coverage rate

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Page 2: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

Pap test for cervical cancer screening A success story

bull Introduce essentially by gynecologists in last 60

(annual control)

bull Opportunist

bull Cytology-based (conventional ndash LBC)

bull HPV for ASCUS triage

Cervical cancer screening Switzerland

Incidence CH 53 100 000NICER Cancer IncidenceSwitzerland wwwnicerorgenstatistics-atlascancerincidenceaccessed 01 08 2014

bull Participation rate Switzerland 70-80ndash Belgium 61ndash Norway 866ndash England 785-835

Richard et al Cancer Epidem 2015Arbyn et al PlosOne 2015Bang et al J Public Health 2012Jeangros et al Eur J Public Health 2016

Swiss CC coverage rate

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Page 3: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

bull Introduce essentially by gynecologists in last 60

(annual control)

bull Opportunist

bull Cytology-based (conventional ndash LBC)

bull HPV for ASCUS triage

Cervical cancer screening Switzerland

Incidence CH 53 100 000NICER Cancer IncidenceSwitzerland wwwnicerorgenstatistics-atlascancerincidenceaccessed 01 08 2014

bull Participation rate Switzerland 70-80ndash Belgium 61ndash Norway 866ndash England 785-835

Richard et al Cancer Epidem 2015Arbyn et al PlosOne 2015Bang et al J Public Health 2012Jeangros et al Eur J Public Health 2016

Swiss CC coverage rate

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Page 4: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

Incidence CH 53 100 000NICER Cancer IncidenceSwitzerland wwwnicerorgenstatistics-atlascancerincidenceaccessed 01 08 2014

bull Participation rate Switzerland 70-80ndash Belgium 61ndash Norway 866ndash England 785-835

Richard et al Cancer Epidem 2015Arbyn et al PlosOne 2015Bang et al J Public Health 2012Jeangros et al Eur J Public Health 2016

Swiss CC coverage rate

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Page 5: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

bull Participation rate Switzerland 70-80ndash Belgium 61ndash Norway 866ndash England 785-835

Richard et al Cancer Epidem 2015Arbyn et al PlosOne 2015Bang et al J Public Health 2012Jeangros et al Eur J Public Health 2016

Swiss CC coverage rate

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Page 6: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Page 7: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Page 8: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
Page 9: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Page 10: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Page 11: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
Page 12: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Page 13: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Page 14: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
Page 15: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
Page 16: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
Page 17: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
Page 18: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Page 19: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Page 20: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Page 21: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Page 22: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
Page 23: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Page 24: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Page 25: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
Page 26: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Page 27: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Page 28: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
Page 29: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
Page 30: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
Page 31: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
Page 32: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Page 33: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Page 34: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

Incidence rates of invasive cervical cancer by region Switzerland 1983-2007

0

2

4

6

8

10

12

1983-87 1988-92 1993-97 1998-02 2003-07

year

Std

rate

s pe

r 100

000

SASL CH

2008-2012

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Page 35: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

Graph5

SA
SL
CH
year
Std rates per 100 000
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Page 36: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

INC ca col

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Incidence
Periods Number of cases Yearly average European standardized rate
1983-87 2023 405 Periods SA SL CH
1988-92 1735 347 1983-87 1119 1108 1115
1993-97 1778 356 1988-92 912 877 902
1998-02 1485 297 1993-97 901 786 868
2003-06 932 233 1998-02 731 589 689
2003-07 534 479 518
Age std rates (European population)
1998-02 69
2003-06 52
Age specific rates - 2003-2007
0- 0
5- 0
10- 0
15- 01
20- 08
25- 31
30- 61
35- 97
40- 93
45- 93
50- 93
55- 71
60- 76
65- 85
70- 8
75- 13
80- 79
85+ 113
Incidence
Crude rates by age-group amp mean annual trends
Periods 0-19 20-49 50-69 70+
1983-87 0 111 2212 2308
1988-92 0 96 1608 1988
1993-97 0 1079 1401 1718
1998-02 003 914 1006 1461
2003-06 004 673 801 1073
Area Rates 2003-2007 95 CI
GRGL 78 21 26
TI 63 15 18
VS 57 15 19
ZH 54 07 08
SA 53 08 09
SGA 53 11 13
CH 52 11 12
SRT 48 06 06
VD 46 09 11
NE 43 17 23
BSBL 4 11 14
GE 38 1 12
FR 36 2 32
Page 37: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

age specific inc rates

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Page 38: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

age specific inc rates

age group
Rates per 100 000
Age specific incidence rates of cervical cancer Switzerland 2003-2007
0
0
0
01
08
31
61
97
93
93
93
71
76
85
8
13
79
113

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Page 39: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

trends inc suisse

0
0
0
01
08
31

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
0-
5-
10-
15-
20-
25-
Page 40: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

trends inc par classe dage

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Page 41: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

trends inc par classe dage

SA
SL
CH
year
Std rates per 100 000
Incidence rates of invasive cervical cancer Switzerland 1983-2007
1119
1108
1115
912
877
902
901
786
868
731
589
689
534
479
518

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Page 42: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

Comp cantons

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
Page 43: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

Comp cantons

0-19
20-49
50-69
70+
year
Crude rates per 100 000
Incidence rates of invasive cervical cancer by age group Switzerland 1983-2006
0
111
2212
2308
0
96
1608
1988
0
1079
1401
1718
003
914
1006
1461
004
673
801
1073

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
1983-87 1983-87 1983-87 1983-87
1988-92 1988-92 1988-92 1988-92
1993-97 1993-97 1993-97 1993-97
1998-02 1998-02 1998-02 1998-02
2003-06 2003-06 2003-06 2003-06
Page 44: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

Mort ca col

Registry
STD rates per 100 000
Incidence of invasive cervical cancer by regional registry Switzerland 2003-2007
78
63
57
54
53
53
52
48
46
43
4
38
36

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
GRGL 26 21
TI 18 15
VS 19 15
ZH 08 07
SA 09 08
SGA 13 11
CH 12 11
SRT 06 06
VD 11 09
NE 23 17
BSBL 14 11
GE 12 1
FR 32 2
Page 45: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

curve morta rates

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Mortality SA CH SL
Periods Number of cases Yearly average Periods
1983-87 885 177 1983-87 453 441 412
1988-92 745 149 1988-92 364 342 288
1993-97 631 126 1993-97 295 274 223
1998-02 456 91 1998-02 196 180 140
2003-06 352 88 2003-07 176 165 140
Age std rates (European population)
1998-02 18
2003-06 17
Mortality
0- 00
5- 00
10- 00
15- 00
20- 00
25- 01
30- 04
35- 08
40- 11
45- 20
50- 23
55- 38
60- 42
65- 54
70- 55
75- 79
80- 101
85+ 104
23
Page 46: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

age spec mort

SA
CH
SL
years
Std rates per 100 000
Mortality rates of invasive cervical cancer Switzerland 1983-2007
45292403095
44087751852
4115611488
36365651298
34191976482
28829893735
29511768691
27434174734
22335853374
19607189035
17967472282
13973465228
17585577482
16519593353
13968953982
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
1983-87 1983-87 1983-87
1988-92 1988-92 1988-92
1993-97 1993-97 1993-97
1998-02 1998-02 1998-02
2003-07 2003-07 2003-07
Page 47: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018
age groups
Rates per 100 000
Age specific mortality rates of cervical cancer Switzerland 2003-2007
0
0
0
0
0
00849015354
03756492158
07851892371
10992421695
20321515404
23382703089
37774780046
41914502037
54133121408
55453610534
7946643962
101023527848
104000876579

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
0-
5-
10-
15-
20-
25-
30-
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
Page 48: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

Cervical cancer is a public health

problem

60 cervical cancer incidence

reduction

False-positive cytology is public

health proble

European countries adopt HPV primary

screening

1970 2015

CytologyScreening

2010

Vaccination

HPV RCT

HPV deacutepistage NL

20201960

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
Page 49: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

Cervical cancer screening in Switzerland

Area to be consideredbull Screening women 20+ (optimal screening intervals)bull Screening women 30+ (potential for primary HPV testing (no Pap))

bull Possible harm from screeningbull Anxiety over a positive testbull Painbleeding from proceduresbull Treatment-related pregnancy complicationsbull Number of colposcopies is a marker for harms

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
Page 50: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

We can imagine thathellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10

Improvement

Nab of intervention

SCREENING INTERVAL

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
Page 51: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

Buthellip

0102030405060708090

100

0 1 2 3 4 5 6 7 8 9 10Nb of intervention Courtesy M Boulvain

SCREENING INTERVAL

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
Page 52: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

About 75-80 of population have HPV exposure hellip and gt95 will clear the infection

About 70-80 () will have CIN1 and most will regress without treatment hellip they have little neoplastic potential and maybe only 1 may develop into a cancer

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
Page 53: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

HPV+ CIN1 CIN2 CIN3

Transient infection (HPV and LSIL)SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
Page 54: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

Transient infection (HPV and LSIL)

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
Page 55: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

HPV+ CIN1 CIN2 CIN3

CA

1 5 20

HEALTHY

9860 50 30

Allow regression of ldquotransientrdquo lesions

gt2 yrs sim 5 yrs sim10 yrs

SCREENING INTERVAL

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
Page 56: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

Ca300

HSIL7000

LSIL30000

ASC-US40000 Based on 12 million testsy

Courtesy P Vassilakos

Cervical cancer is not a main public health concern in Switzerland

Abnormal Pap

are major public health concerns

Cytology-based screening false positive rateSCREENING INTERVAL

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
Page 57: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

Benefits HarmsOver-diagnosisOver-treatment

Anxiety Prevent CancerReduce MorbidityMortality

Determine the level of risk that is acceptable and the harms of screening

Optimize the screening SCREENING INTERVAL

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
Page 58: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

HPV and Cervical Cancer

Over 99 of cervical cancers have HPV DNA detected within the tumor

70 of cervical cancer is caused by one of two types of HPV 16 or 18

HPV TESTING lt30

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
Page 59: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

Murphy et al 2012 JOGC

HPV TESTING lt30

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
Page 60: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

Cumulative Incidence of CIN3+

Dillner et al BMJ 2008

HPV TESTING lt30

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
Page 61: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

Benefice of HPV testing

bull Increased detection of prevalent CIN3

bull Decreased CIN3 in subsequent screening rounds

bull Enhances detection of adenocarcinomaAIS

bull Minimizes the increased number of colposcopies thus it reduces harms

HPV TESTING lt30

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
Page 62: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

Reminder ndash Swiss policy 2012

Age Screening interval21 ndash 30 years 2 years31 ndash 70 years 3 years

2012

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
Page 63: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

Swiss policy2018

WWWSGGGCH

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
Page 64: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

Swiss policy 2018

Age Screening interval21 ndash 30 yrs 3 years cytology31 ndash 70 yrs 3 years cytology or HPV with triage

cytology

2018

Doesnrsquot include CIN2 CIN3 women infected with HIV or immunocompromised (solid organ transplants)

21 ndash 70 yrs Every 3 years

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
Page 65: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

Swiss policy 2018 (21-29 yrs old)

1 Women lt21 yrs should not be screened regardless of age of sexual onset and other behavior-related risk factors

2 Women gt21 yrs who no sexual intercourse may not need a Pap test (to be decided women and physician)

3 Women 21-29 yrs cytology alone every 3 years

4 Recommend against ldquohellip three consecutive annual cytology beforehelliprdquo

5 Recommend against HPV testing (alone or in combination with cytology) in women aged lt30 years

6 Vaccinated = unvaccinated

2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
Page 66: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

Swiss policy 2018 (30-70 yrs old)

1 Women 30-70 yrs every 3 years HPV testing (alone) or cytology

2 If HPV ndash women should be informed about the HPV price (no reimbursement)

3 If HPV - screening should begin 3 years after the last negative cytology

4 Recommend against co-testing (concomitant HPV and cytology)

5 Recommend against testing HPV low-risk

2018

Women and physician choice

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
Page 67: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

Swiss policy 2018 (stop)

1 Stop at age 71 for women with adequate negative prior screening (no CIN2+)

2 Stop after hysterectomy with removal of cervix (no history of CIN2+)

2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
Page 68: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

Age Screening interval

coverage rate

IncidenceCancer cervical

100 000Belgium 25-64 3 58 93Denmark 23-65 3-5 75 126England 25-64 3 agrave 5 83 83Finland 30-65 5 80 43France 25-65 3 69 98Italy 25-64 3 53-74 81Netherland 30-60 5 77 73Spain 20-64 3 agrave 5 496 76Switzerland 21-70 3 72 52Sweden 23-60 3 83 82

Cervical Cancer Screening Programs in 19 ICSN Countries 2012 Organization Policies

and Program Reach JNCI 2017

Swiss policy 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
Page 69: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

Norway - 4 countiesHPV primary screening

Sweden ndash HPV primary screening

England - HPV as primary screening

Netherlands - HPV primary screening (implemented)

Italy - 3 counties HPV primary screening

Finland - HPV primary screening in guidelines

Adapted from Melchers

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
Page 70: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

Disparity between guidelines and practice -Anecdotes

ldquoWomen were savedrdquo by a pap test in young agehellip

ldquoI discover a HSIL at 16 years oldrdquo

ldquoWomen were saved she was 72 years oldrdquo

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
Page 71: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

bull From women perspectivendash New recommendation may appear to decrease service for the

purpose of saving money for insurer

ndash Many women are not interested in assuming more cancer risk even if the harm is significant

bull Improve quality and lower costs of care for patients

Perception of change

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
Page 72: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

Perception of change

bull From Healthcare provider perspective- Consider Pap smears to be part of every womanrsquos annual visit

- Women will not come for an annual check-up and may be less inclined to undergo screening

bull Do not minimize harm from overusehellip practicing medicine according to guideline is a strong appeal to our professionalism

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
Page 73: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

Conclusion

bull Provider must understand guidelines and reasons behind (harm and benefit)

bull Must explain to patients controversies (when to start interval and stopping)

bull Must help women to make their own decisions

bull Biggest gain would screening among women neverrarely screened

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
Page 74: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

Thank you for your attention

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
Page 75: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

Case ndash Swiss policy

A 45 yo new patient who says she has ldquoalwaysrdquo had a Pap test and would like to have a cervical cancer screening

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
Page 76: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

Case ndash Swiss policy

You recommend

1 HPV test

2 Pap test

3 Co-testing

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
Page 77: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

Case ndash Swiss policy

You recommend

1 Annually

2 Every two years

3 Every three years

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
Page 78: Recommandations SSGO dépistage cancer du col utérin©sentations/GRSSGO mars... · dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018

Case ndash Swiss policy

Lifetime risk of colposcopy

bull Pap test 3 yrs 760 colpos1000 women

bull Pap test 2 yrs 1080 colpos1000 women

bull Pap test 1 yr 2000 colpos1000 women

Stout NK et al Arch Intern Med 2008168181

  • Diapositive numeacutero 1
  • Diapositive numeacutero 2
  • Diapositive numeacutero 3
  • Diapositive numeacutero 4
  • Diapositive numeacutero 5
  • Diapositive numeacutero 6
  • Diapositive numeacutero 7
  • Diapositive numeacutero 8
  • Diapositive numeacutero 9
  • Diapositive numeacutero 10
  • We can imagine thathellip
  • Buthellip
  • Transient infection (HPV and LSIL)
  • Diapositive numeacutero 14
  • Diapositive numeacutero 15
  • Diapositive numeacutero 16
  • Diapositive numeacutero 17
  • Diapositive numeacutero 18
  • HPV and Cervical Cancer
  • Diapositive numeacutero 20
  • Cumulative Incidence of CIN3+
  • Benefice of HPV testing
  • Reminder ndash Swiss policy 2012
  • Swiss policy
  • Swiss policy 2018
  • Swiss policy 2018 (21-29 yrs old)
  • Swiss policy 2018 (30-70 yrs old)
  • Swiss policy 2018 (stop)
  • Swiss policy 2018
  • Diapositive numeacutero 30
  • Disparity between guidelines and practice - Anecdotes
  • Diapositive numeacutero 32
  • Diapositive numeacutero 33
  • Conclusion
  • Diapositive numeacutero 35
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy
  • Case ndash Swiss policy